Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Non-Current Assets over the past 3 years, most recently at $48.3 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $48.3 million for Q4 2025, up 10.04% from a year ago — trailing twelve months through Dec 2025 was $179.8 million (down 24.65% YoY), and the annual figure for FY2025 was $48.3 million, up 10.04%.
  • Non-Current Assets for Q4 2025 was $48.3 million at Tonix Pharmaceuticals Holding, up from $44.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TNXP hit a ceiling of $108.4 million in Q2 2023 and a floor of $43.3 million in Q1 2025.
  • Median Non-Current Assets over the past 3 years was $46.7 million (2024), compared with a mean of $69.7 million.
  • Peak annual rise in Non-Current Assets hit 10.36% in 2024, while the deepest fall reached 58.86% in 2024.
  • Tonix Pharmaceuticals Holding's Non-Current Assets stood at $106.7 million in 2023, then crashed by 58.86% to $43.9 million in 2024, then increased by 10.04% to $48.3 million in 2025.
  • The last three reported values for Non-Current Assets were $48.3 million (Q4 2025), $44.4 million (Q3 2025), and $43.8 million (Q2 2025) per Business Quant data.